Physician profile
Samuel Mcelroy
NPI 1023302544
$4,238.50
in general payments reported to CMS, 2019-2025
32 companies · $204 in 2025
The $204 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $634 · 2020: $509 · 2021: $1,655 · 2022: $1,138 · 2023: $80.06 · 2024: $18.08 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $302.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $692.42 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $463.65 | 2019-2025 | |
| Novo Nordisk INC | $461.03 | 2019-2022 | |
| Amgen INC. | $441.68 | 2019-2025 | Repatha, Otezla |
| Astellas Pharma US INC | $266.83 | 2019-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $247.37 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $208.96 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $182.10 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.28 | 2020-2022 | |
| Esperion Therapeutics, INC. | $147.18 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $108.85 | 2020-2023 | Pifeltro, Dificid, Delstrigo |
| Pfizer INC. | $84.02 | 2019-2021 | |
| Lilly USA, LLC | $78.47 | 2021-2023 | Mounjaro |
| Biohaven Pharmaceuticals, INC. | $77.39 | 2020-2021 | |
| Boston Scientific Corporation | $66.93 | 2019-2025 | Watchman Flx |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $59.90 | 2021 | |
| Amarin Pharma, INC. | $59.83 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.28 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $46.48 | 2019-2021 | |
| Abbott Laboratories | $46.44 | 2022-2023 | Freestyle Libre 3 |
| Eisai INC. | $41.14 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $40.18 | 2022 | |
| Radius Health, INC. | $37.40 | 2019 | |
| Paratek Pharmaceuticals, INC. | $24.61 | 2021 | |
| Allergan, INC. | $23.57 | 2020 | |
| Neos Therapeutics, LP | $20.18 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $18.08 | 2024 | Eliquis |
| Biogen, INC. | $15.37 | 2021 | |
| Dexcom, INC. | $15.31 | 2021 | |
| Horizon Therapeutics Plc | $14.60 | 2019 | |
| Optinose US, INC. | $12.73 | 2021 | |
| Supernus Pharmaceuticals, INC. | $11.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Mcelroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.